IRIS
GERRATANA, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.037
AS - Asia 3.106
EU - Europa 1.677
SA - Sud America 504
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 11.395
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.926
SG - Singapore 1.524
CN - Cina 609
BR - Brasile 423
IT - Italia 348
HK - Hong Kong 345
DE - Germania 335
VN - Vietnam 261
RU - Federazione Russa 196
UA - Ucraina 177
IN - India 126
GB - Regno Unito 100
IE - Irlanda 80
FI - Finlandia 70
SE - Svezia 67
CA - Canada 57
TR - Turchia 44
KR - Corea 43
FR - Francia 38
PL - Polonia 38
AT - Austria 34
BE - Belgio 34
NL - Olanda 33
JP - Giappone 32
CZ - Repubblica Ceca 30
AR - Argentina 29
MX - Messico 27
ZA - Sudafrica 26
BD - Bangladesh 21
ES - Italia 20
CH - Svizzera 16
LT - Lituania 16
RO - Romania 15
IR - Iran 12
CO - Colombia 11
EC - Ecuador 11
ID - Indonesia 11
IQ - Iraq 11
VE - Venezuela 10
AE - Emirati Arabi Uniti 8
EG - Egitto 8
PY - Paraguay 8
PK - Pakistan 7
MA - Marocco 6
AZ - Azerbaigian 5
CL - Cile 5
EE - Estonia 5
IL - Israele 5
JM - Giamaica 4
KZ - Kazakistan 4
LA - Repubblica Popolare Democratica del Laos 4
LB - Libano 4
LV - Lettonia 4
NO - Norvegia 4
SA - Arabia Saudita 4
TG - Togo 4
AL - Albania 3
AM - Armenia 3
BO - Bolivia 3
DK - Danimarca 3
DZ - Algeria 3
EU - Europa 3
HN - Honduras 3
NI - Nicaragua 3
PA - Panama 3
SN - Senegal 3
TN - Tunisia 3
UY - Uruguay 3
AU - Australia 2
BB - Barbados 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KE - Kenya 2
KG - Kirghizistan 2
MY - Malesia 2
OM - Oman 2
RS - Serbia 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AF - Afghanistan, Repubblica islamica di 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CM - Camerun 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
GT - Guatemala 1
HT - Haiti 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
LC - Santa Lucia 1
Totale 11.378
Salva come PNG Salva come JPEG
Città #
Ashburn 831
Fairfield 716
Singapore 697
Chandler 446
Woodbridge 346
Hong Kong 343
Seattle 305
Beijing 283
Houston 277
Wilmington 242
Cambridge 227
Ann Arbor 207
Boardman 145
Los Angeles 136
Frankfurt am Main 129
Dearborn 115
New York 108
Jacksonville 98
Princeton 76
Dublin 75
Dallas 74
Ho Chi Minh City 73
Munich 68
Buffalo 65
Dong Ket 64
Udine 54
Hefei 50
Hanoi 44
São Paulo 44
Redondo Beach 42
Seoul 42
San Diego 39
Warsaw 37
Washington 34
Montreal 31
Tokyo 30
Brussels 29
Santa Clara 29
Izmir 27
Martignacco 26
Redmond 26
Stockholm 26
Brno 25
Ogden 24
Denver 23
Des Moines 23
London 22
Turku 22
Nuremberg 21
Phoenix 21
Brooklyn 20
Chennai 20
Orem 20
Belluno 18
Johannesburg 18
Boston 16
Chicago 16
Guangzhou 16
Poplar 16
Vienna 16
Zurich 15
Helsinki 14
Milan 14
Lappeenranta 13
Mexico City 13
Rome 13
Falls Church 12
Nanjing 12
Norwalk 12
San Francisco 12
Düsseldorf 11
Hyderabad 11
Mumbai 11
Shanghai 11
Trieste 11
Ankara 10
Belo Horizonte 10
Council Bluffs 10
Da Nang 10
Jinan 10
Lauterbourg 10
Leawood 10
Naples 10
The Dalles 10
Amsterdam 9
Arezzo 9
Augusta 9
Charlotte 9
Timisoara 9
Toronto 9
City of London 8
Manchester 8
Xi'an 8
Atlanta 7
Biên Hòa 7
New Delhi 7
Newark 7
San Jose 7
Brasília 6
Cairo 6
Totale 7.513
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 203
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 197
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 182
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 177
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 175
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 169
Pattern of metastasis and outcome in patients with breast cancer 161
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 160
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 159
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 158
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 158
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 157
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 156
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 151
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 148
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 148
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 147
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 144
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 143
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 141
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 140
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 140
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 134
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 132
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 132
Do platinum salts fit all triple negative breast cancers? 130
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 129
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 129
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 129
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 125
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 125
Determinants of Last-line Treatment in Metastatic Breast Cancer 123
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 123
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 122
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 122
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 122
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 118
International expert consensus on the clinical integration of circulating tumor cells in solid tumors 117
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 115
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 114
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 114
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 113
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 113
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 112
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 112
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 111
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 111
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 108
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 105
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 104
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 103
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 102
Risk factors and survival outcomes in patients with brain metastases from breast cancer 102
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 101
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 98
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 97
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 96
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 95
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 94
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 94
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 94
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 91
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 88
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 87
null 84
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 82
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 82
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 81
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 81
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 79
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 77
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 77
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China 74
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 73
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 72
Time to surgery after neoadjuvant chemotherapy for early breast cancer 71
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 71
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 71
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling 68
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 65
The puzzling clinical presentation of fluoropyrimidines cardiotoxicity 65
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 65
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 65
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 63
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 61
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology 60
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 60
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 60
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach 58
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 56
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects 55
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics 55
The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives 55
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies 55
Editorial: Cancer evolution: From biological insights to therapeutic opportunities 54
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them 53
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer 52
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 50
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 50
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer 50
Totale 10.550
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.847
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.847
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021689 0 0 0 0 0 72 85 143 81 69 108 131
2021/2022753 88 69 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/20252.566 130 158 97 107 186 119 175 145 315 172 413 549
2025/20263.314 576 516 382 562 867 411 0 0 0 0 0 0
Totale 11.848